Diffuse Large B-cell Lymphoma
332
55
88
123
Key Insights
Highlights
Success Rate
70% trial completion
Published Results
76 trials with published results (23%)
Research Maturity
123 completed trials (37% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
16.0%
53 terminated out of 332 trials
69.9%
-16.6% vs benchmark
15%
50 trials in Phase 3/4
62%
76 of 123 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 123 completed trials
Clinical Trials (332)
Study of Out of Specification for Tisagenlecleucel
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Preliminary Assessment of [18F]BL40 in PET/CT Scans
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)